Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a significant milestone in its Advance-HTN trial by hitting its enrollment target of 261 participants. This pivotal trial is crucial in …
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial Read More